Background {#Sec1}
==========

In critically ill patients, the incidence of acute kidney injury (AKI) is high - 39% in the recent prospective, observational, multicenter study, the Finnish Acute Kidney Injury (FINNAKI) study, which was conducted in Finnish intensive care units (ICUs) \[[@CR1]\]. In other prospective studies in critically ill patients the incidence of AKI is reported as 24--66% \[[@CR2], [@CR3]\]. Although the pathophysiology of AKI has been investigated, there is no single explanation for the condition due to the multifactorial nature of the syndrome. Sepsis is the most common factor predisposing to AKI in the critically ill. In patients with sepsis the incidence of AKI is 31--53% \[[@CR4]--[@CR6]\] and in patients with septic shock it is even higher, at 47--61% \[[@CR7], [@CR8]\]. The previously identified risk factors for septic AKI, such as age, sex, and baseline comorbidities, have failed to reliably predict individual risk of septic AKI \[[@CR9]\]. Thus, it is plausible that genetic variability between individuals may explain a significant part of the risk.

Genetic predisposition to AKI has been previously studied in candidate genes, by testing associations between single nucleotide polymorphisms (SNP) from candidate genes and a phenotype. Our recent systematic review confirmed that despite some positive associations there are no conclusive data \[[@CR10]\]. A study by Frank et al*.* \[[@CR11]\] provided one of the very first hypothesis-free approaches to septic AKI; it comprised 887 patients in septic shock defined according to American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) criteria \[[@CR12]\], who were genotyped using a large-scale genotyping microarray. In this study, five SNPs were associated with AKI after validating the results in an additional sample. Interestingly, the associated SNPs are in the apoptosis pathway genes. The SNP rs8094315 and SNP rs12457893 are located in the intron of *B-cell CLL/lymphoma 2 (BCL2)* --gene. The SNPs rs2093266 in the *serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4 (SERPINA4)* gene and SNP rs1955656 in the *serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 (SERPINA5)* gene are in complete linkage disequilibrium (LD). There was also association between the SNP rs625145 in the *salt-inducible kinase family 3 (SIK3)* gene and AKI. In this study we aimed to replicate the aforementioned findings \[[@CR9]\] in a prospective cohort of critically ill patients with sepsis.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This study is a predetermined genetic study of the prospective, observational, multicenter FINNAKI study, in which patients were recruited from 17 Finnish ICUs. Details of the FINNAKI study have been published elsewhere \[[@CR1]\] and are presented in Additional file [1](#MOESM1){ref-type="media"}. The Ethics Committee of the Department of Surgery in Helsinki University Hospital approved the study. An informed separate written consent for genetic samples was obtained from the patient or next of kin at the initiation, with the option of deferred consent. The main study ended on 1 February 2012, and recruitment was extended until 30 April 2012 to achieve an adequate number of patients with sepsis. The study was conducted according to the Declaration of Helsinki.

Data collection {#Sec4}
---------------

We collected the study-specific data items (approximately 80% of the data) on admission and daily until day 5 or ICU discharge using an electronic case report form (CRF). Data comprised previous and current health status, medication, risk factors for AKI, laboratory values and operations preceding ICU admission, sepsis and related organ dysfunctions, and focus of infection. Presence of AKI and/or sepsis was screened until ICU discharge or day 5 at the latest if the patient was still in the ICU. Routine data were collected with the help of the Finnish Intensive Care Consortium, which consists of 25 ICUs nationwide.

Definitions {#Sec5}
-----------

For staging of AKI, plasma creatinine was measured daily and urine output hourly. We defined and staged AKI according to the new Kidney Disease: Improving Global Outcomes (KDIGO) AKI criteria \[[@CR13]\]. We sought to compare patients with a severe phenotype of AKI (KDIGO stage 2--3) to patients with no AKI. Thus, we excluded patients with KDIGO stage-1 AKI from the current analysis because their phenotype may be seen as indecisive. We defined sepsis and septic shock according to the ACCP/SCCM definitions \[[@CR12]\], a definition also used in the previous report \[[@CR11]\].

Blood sampling and DNA extraction {#Sec6}
---------------------------------

Whole blood was collected at enrollment and after separation of plasma, stored at -80 °C for subsequent DNA extraction. DNA was isolated on a Chemagic 360 instrument (Perkin Elmer, Baesweiler, Germany), based on magnetic bead technology, using a Chemagic DNA Blood10k Kit according to the manufacturer's instructions. DNA concentrations were determined using UV light and PicoGreen methods, and samples were diluted into 10 ng/μl for genotyping.

Genotype analysis {#Sec7}
-----------------

Genotyping was performed at the Technology Centre of the Institute for Molecular Medicine Finland (FIMM), University of Helsinki. The genotyping was done using Agena MassARRAY® system and the iPLEX^TM^ Gold Assay (Agena Bioscience^TM^, San Diego, CA, USA). This method has excellent success (\>95%) and accuracy (100%) \[[@CR14]\]. Genotyping reactions were performed on 20 ng of dried genomic DNA in 384-well plates according to the manufacturer's recommendations and using their reagents \[[@CR15]\]. Both polymerase chain reaction (PCR) and extension primers were designed using MassARRAY Assay Design software (Agena Bioscience^TM^) (Additional file [2](#MOESM2){ref-type="media"}). The data were collected using the MassARRAY Compact System (Agena Bioscience^TM^) and the genotypes were called using TyperAnalyzer software (Agena Bioscience^TM^).

We examined genotyping quality by a detailed quality control procedure consisting of success rate check, duplicated samples, water controls, and Hardy-Weinberg equilibrium (HWE) testing. In addition, the genotype calls were checked manually and corrected when necessary. Genotyping personnel were blinded to the clinical status of the patients.

Statistical analysis {#Sec8}
--------------------

We compared the clinical and demographic variables to test for significant differences between groups using the Fisher exact test for categorical variables and the Mann-Whitney *U* test for continuous variables. We present data as medians and interquartile ranges, or absolute values and percentages. Statistical analyses of the demographic and clinical variables were performed using the SPSS Statistics version 22 (IBM Corp., Armonk, NY, USA).

Associations between AKI and SNP were adjusted for clinical characteristics that differed significantly between patients with and without AKI. In addition to the univariate analysis we performed multivariate analysis using logistic regression by entering variables, selecting characteristics with a *p* value \<0.2 in univariate analysis. The percentage of missing data was 15.9%. The missing data were imputed on the assumption of being unaffected for categorical variables and on the median for continuous variables.

Genetic association tests were performed using logistic regression and the PLINK software \[[@CR16]\]. As in the previous study an additive genetic model was assumed. However, confirmatory tests were performed using recessive and dominant genetic models. In the primary analysis patients with sepsis and AKI (KDIGO stage 2--3) were compared to patients with sepsis but no AKI. Secondary analyses were performed including cases and controls from the entire cohort, and was performed separately only in those with septic shock. As this was a replication study, we considered all *p* values \<0.05 significant.

Power calculations {#Sec9}
------------------

Power calculations were made using Genetic Power Calculator \[[@CR17]\], assuming allele frequencies and odds ratios from the validation cohort from the study by Frank et al*.* \[[@CR11]\], and with the assumption of 299 patients and 354 controls, a prevalence of AKI of 39,% and a type I error rate of 0.005. For detailed power calculations for each SNP see Additional file [3](#MOESM3){ref-type="media"}.

Results {#Sec10}
=======

Patients {#Sec11}
--------

We prospectively enrolled 2968 ICU patients in the FINNAKI genetic study, as presented in the study flowchart (Fig. [1](#Fig1){ref-type="fig"}). After excluding ineligible patients, there were 2567 critically ill patients, of whom 837 (32.6%) had sepsis. Of these, 299 (35.7% of the 837) patients developed KDIGO stage 2--3 AKI and 354 (42.3% of 837) patients with no AKI served as controls (Fig. [1](#Fig1){ref-type="fig"}, orange dashed line). Thus, the genetic associations were studied among 653 patients with sepsis, of whom 478 (73.2%) had septic shock. Among patients with septic shock, 252 (40.2% of 627) had severe AKI and 226 (36.0% of 627) did not have AKI (Fig. [1](#Fig1){ref-type="fig"}, red dashed line). In the entire genetic cohort, there were 601 (23.4% of 2567) patients who developed KDIGO stage 2--3 AKI and 1545 (60.2% of 2567) patients who did not develop AKI (Fig. [1](#Fig1){ref-type="fig"}, blue dashed line).Fig. 1Study flowchart. *AKI* acute kidney injury, *KDIGO* Kidney Disease: Improving Global Outcomes, *FINNAKI* Finnish Acute Kidney Injury study

The baseline characteristics of the patients with sepsis who did and did not have AKI are presented in Table [1](#Tab1){ref-type="table"}. The baseline characteristics of the patients with septic shock who did and did not have AKI are presented in Table [2](#Tab2){ref-type="table"}. The baseline characteristics of the entire cohort are presented in Additional file [4](#MOESM4){ref-type="media"}.Table 1Demographic and baseline characteristics of the patients with sepsis according to the presence of acute kidney injuryCharacteristicsPatients with data available, *n*KDIGO 0\
(n = 354)KDIGO 2--3\
(n = 299)All patients\
(n = 653)*P* valueAge (years)65363 (52--73)65 (54.5--75)63 (53--74)0.046Gender (male)653234 (66.1%)183 (61.2%)417 (63.9%)0.195BMI (kg/m^2^)65126.0 (23.1--29.2)27.3 (24.5--30.8)26.5 (23.5--29.6)0.001Arterial hypertension651164 (46.6%)159 (53.2%)323 (49.6%)0.099Diabetes65368 (19.2%)82 (27.4%)150 (23.0%)0.015Arteriosclerosis64836 (10.3%)42 (14.1%)78 (12.0%)0.147COPD64945 (12.8%)19 (6.4%)64 (9.9%)0.008Chronic liver disease64717 (4.9%)24 (8.1%)41 (6.3%)0.106Systolic heart failure64939 (11.1%)24 (8.1%)63 (9.7%)0.231Thromboembolus64926 (7.4%)17 (5.7%)43 (6.6%)0.432Rheumatic disease64826 (7.4%)18 (6.1%)44 (6.8%)0.534Serum creatinine Baseline (μmol/L)65380.3 (68.0--94.0)77.0 (66.5--93.0)79.0 (67.0--93.2)0.318 Maximum (μmol/L)60472.0 (55.0--89.0)227.0 (166.0--321.0)106.5 (68.5--221.5)\<0.001Pre-ICU daily medication ACE inhibitor or ARB640113 (32.6%)115 (39.2%)228 (35.6%)0.082 NSAID62433 (9.7%)42 (14.7%)75 (12.0%)0.064 Aspirin64581 (23.1%)73 (24.7%)154 (23.9%)0.644 Diuretic64393 (26.8%)88 (29.7%)181 (28.1)0.429 Metformin64748 (13.7%)47 (15.8%)95 (14.7%)0.504 Statin64486 (24.6%)79 (26.8%)165 (25.6%)0.587 Immunosuppressives64629 (8.3%)28 (9.5%)57 (8.8%)0.581 Corticosteroids64941 (11.6%)32 (10.8%)73 (11.2%)0.803 Warfarin64739 (11.1%)41 (13.8%)80 (12.4%)0.338Treatments administered 48 h before admission Contrast medium65283 (23.5%)51 (17.1%)134 (20.6%)0.052 Aminoglycoside antibiotics6534 (1.1%)5 (1.7%)9 (1.4%)0.739 Peptidoglycan antibiotics65317 (4.8%)11 (3.7%)28 (4.3%)0.563 ACE inhibitor or ARB64177 (22.1%)72 (24.7%)149 (23.2%)0.454 NSAID61552 (15.6%)40 (14.2%)92 (15.0%)0.651 Amfoterisin B6531 (0.3%)2 (0.7%)3 (0.5%)0.596 Diuretics637119 (34.6%)117 (39.9%)236 (37.0%)0.188 Colloids (gelatin or starch)620102 (30.8%)117 (40.5%)219 (35.3%)0.015 Albumin6474 (1.1%)6 (2.0%)10 (1.5%)0.526 Emergency admission648343 (98.0%)292 (98.0%)635 (98.0%)1.0 Operative admission65288 (24.9%)66 (22.1%)154 (23.6%)0.459 SAPS II score 24 h without renal and age components64924.0 (17.0--30.0)26.0 (20.0--37.0)25.0 (18.0--33.0)\<0.001 Mechanical ventilation653234 (66.1%)221 (73.9%)455 (69.7%)0.033 White blood cell count, maximum (10^9^/L)58311.8 (7.9--16.5)12.2 (7.6--17.8)11.9 (7.7--17.2)0.469 Platelet count, minimum (10^9^/L)632199.5 (141.0--271.0)184.0 (112.0--259.0)191.5 (128.5--265.0)0.028Source of infection653\<0.001 Lung181 (51.1%)100 (33.4%)281 (43.0%) Abdomen62 (17.5%)78 (26.1%)140 (21.4%) Urinary tract10 (2.8%)26 (8.7%)36 (5.5%) Skin25 (7.1%)26 (8.7%)51 (7.8%) Others19 (5.4%)9 (3.0%)28 (4.3%) Multiple sources21 (5.9%)16 (5.4%)37 (5.7%) Unknown source of infection36 (10.2%)44 (14.7%)80 (12.3%)Results presented as median (interquartile range) for continuous variables and total number (percent of affected in a group) for categorical variables. Continuous variables analyzed by the independent samples Mann-Whitney *U* test and categorical variables by Fisher's exact test. *KDIGO* Kidney Disease: Improving Global Outcomes, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *AR* *B* angiotensin receptor blocker, *NSAID* non-steroidal anti-inflammatory drug, *ACE* angiotensin-converting enzyme, *SAPS* simplified acute physiology score Table 2Demographic and baseline characteristics of patients with septic shock according to the presence of acute kidney injuryCharacteristicsPatients with data available, *n*KDIGO 0\
(n = 226)KDIGO 2--3\
(n = 252)All patients\
(n = 478)*P* valueAge (years)47863.0 (52.0--73.0)64.5 (54.0--75.0)63.5 (53.0--74.0)0.138Gender (male)478155 (68.6%)156 (61.9%)311 (65.1%)0.149BMI (kg/m^2^)47626.0 (23.0--29.0)27.3 (24.5--30.5)26.5 (23.5--29.5)0.001Arterial hypertension476104 (46.4%)137 (54.4%)241 (50.6%)0.098Diabetes47842 (18.6%)65 (25.8%)107 (22.4%)0.062Arteriosclerosis47521 (9.4%)36 (14.3%)57 (12.0%)0.120COPD47428 (12.5%)19 (7.6%)47 (9.9%)0.090Chronic liver disease47310 (4.5%)22 (8.8%)32 (6.8%)0.069Systolic heart failure47522 (9.8%)22 (8.8%)44 (9.3%)0.752Thromboembolus47514 (6.2%)14 (5.6%)28 (5.9%)0.846Rheumatic diseases47519 (8.5%)17 (6.8%)36 (7.6%)0.493Serum creatinine Baseline (μmol/L)47882.5 (69.0--93.4)77.0 (67.0--93.0)79.7 (67.0--93.0)0.236 Maximum (μmol/L)47869.0 (50.0--89.0)226.5 (166.0--323.0)113.5 (67.0--230.0)\<0.0001Pre-ICU daily medication ACE inhibitor or ARB46578 (35.6%)96 (39.0%)174 (37.4%)0.502 NSAID45321 (9.8%)35 (14.6%)56 (12.4%)0.152 Aspirin47152 (23.4%)59 (23.7%)111 (23.6%)1.000 Diuretic46857 (26.0%)76 (30.5%)133 (28.4%)0.305 Metformin47330 (13.5%)38 (15.2%)68 (14.4%)0.602 Statin46955 (24.9%)61 (24.6%)116 (24.7%)1.000 Immunosuppressives47119 (8.5%)26 (10.5%)45 (9.6%)0.531 Corticosteroids47426 (11.6%)29 (11.6%55 (11.6%)1.000 Warfarin47226 (11.7%)34 (13.6%)60 (12.7%)0.581Treatments administered 48 h before admission Contrast medium47758 (25.8%)46 (18.3%)104 (21.8%)0.059 Aminoglycoside antibiotics4782 (0.9%)5 (2.0%7 (1.5%)0.455 Peptidoglycan antibiotics47812 (5.3%)10 (4.0%)22 (4.6%)0.519 ACE inhibitor or ARB46843 (19.3%)62 (25.3%)105 (22.4%)0.122 NSAID44828 (13.4%)36 (15.1%)64 (14.3%)0.685 Amfoterisin B4780 (0.0%)2 (0.8%)2 (0.4%)0.500 Diuretics46470 (32.1%)97 (39.4%)167 (36.0%)0.121 Colloids (gelatin or starch)45276 (36.4%)105 (43.2%)181 (40.0%)0.149 Albumin4744 (1.8%)6 (2.4%)10 (2.1%)0.756 Emergency admission474217 (97.3%)245 (97.6%)462 (97.5%)1.000 Operative admission47769 (30.5%)58 (23.1%)127 (26.6%)0.078 SAPS II score 24 h without renal and age components47525.0 (19.0--33.0)26.0 (21.0--37.0)26.0 (20.0--35.0)0.054 Mechanical ventilation478177 (78.3%)197 (78.2%)374 (78.2%)1.000 White blood cell count, maximum (10^9^/L)42812.1 (8.7--16.8)12.8 (7.6--18.7)12.3 (8.1--17.4)0.794 Platelet count, minimum (10^9^/L)458191.0 (140.0--260.0)177.0 (108.5--259.0)185.0 (121.0--259.0)0.065Source of infection4780.001 Lung114 (50.4%)83 (32.9%)197 (41.2%) Abdomen46 (20.4%)68 (27.0%)114 (23.8%) Urinary tract7 (3.1%)20 (7.9%)27 (5.6%) Skin16 (7.1%)22 (8.7%)38 (7.9%) Others11 (4.9)8 (3.2%)19 (4.0%) Multiple sources13 (5.8%)14 (5.6%)27 (5.6%) Unknown source of infection19 (8.4%)37 (14.7%)56 (11.7%)Results presented as median (interquartile range) for continuous variables and total number (percent of affected in a group) for categorical variables. Continuous variables analyzed by the independent samples Mann-Whitney *U* test and categorical variables by Fisher's exact test. *KDIGO* Kidney Disease: Improving Global Outcomes, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *AR* *B* angiotensin receptor blocker, *NSAID* non-steroidal anti-inflammatory drug, *ACE* angiotensin-converting enzyme, *SAPS* simplified acute physiology score

Genetic associations {#Sec12}
--------------------

All of the polymorphisms tested were in HWE. None of the five SNPs investigated, rs8094315 (odds ratio (OR) 1.10, *p* = 0.48), rs12457893 (OR 1.02, *p* = 0.87), rs2093266 (OR 0.77, *p* = 0.15), rs1955656 (OR 0.77, *p* = 0.15), and rs625145 (OR 0.88, *p* = 0.38), was significantly associated with AKI in our analysis in patients with sepsis in the additive genetic model (Table [3](#Tab3){ref-type="table"}). The SNPs rs2093266 and rs1955656 are in complete linkage disequilibrium (LD) and thus present identical results.Table 3Association between acute kidney injury and the polymorphisms studied in 653 patients with sepsis (additive genetic model)UnivariateMultivariateSNPChrBase-pair positionGene and alleles (major/minor)Minor allele frequency^a^Odds ratio\
(95% CI)*P* valueOdds ratio\
(95% CI)^b^*P* valuers62514511116857220*SIK3* A/T0.20/0.210.88 (0.67--1.17)0.380.93 (0.68--1.25)0.62rs19556561494579038*SERPINA5* G/A0.10/0.120.77 (0.53--1.10)0.150.75 (0.51--1.10)0.14rs20932661494566450*SERPINA4* G/A0.10/0.120.77 (0.53--1.10)0.150.75 (0.51--1.10)0.14rs80943151863268814*BCL2* A/G0.24/0.221.10 (0.85--1.43)0.481.08 (0.81--1.43)0.61rs124578931863258928*BCL2* A/C0.37/0.371.02 (0.81--1.29)0.871.06 (0.82--1.36)0.67^a^Patients/controls. ^b^Adjusted for age, body mass index, diabetes mellitus, mechanical ventilation, minimum platelet count, use of non-steroidal anti-inflammatory drugs as daily medication, chronic pulmonary obstructive disease, administration of contrast medium prior to ICU admission, administration of colloids prior to ICU admission, simplified acute physiology score II without age or renal components, operative admission, and source of infection. *SNP* single nucleotide polymorphism, *Chr* chromosome

In logistic regression analysis in patients with sepsis, higher body mass index (BMI), not having chronic obstructive pulmonary disease (COPD), use of non-steroidal anti-inflammatory drugs (NSAID) as daily medication, administration of contrast medium prior to ICU admission, simplified acute physiology score II (SAPS II) without renal or age components, and source of infection were significantly associated with KDIGO stage 2--3 AKI (Additional file [5](#MOESM5){ref-type="media"}). Adjustment for these clinical and demographic factors in the patients with sepsis did not change the results for genetic association, which were not statistically significant (Table [3](#Tab3){ref-type="table"}).

In patients with septic shock, none of the investigated SNPs was significantly associated with AKI in univariate analysis (Table [4](#Tab4){ref-type="table"}). After adjusting for clinical and demographic variables that remained significant in logistic regression (BMI, use of NSAID as daily medication, arteriosclerosis, COPD, administration of contrast medium prior to ICU admission, administration of colloids prior to ICU admission, SAPS II without age or renal components, operative admission, and source of infection (Additional file [6](#MOESM6){ref-type="media"})) SNPs rs2093266 and rs1955656 were significantly associated with AKI (OR 0.63, 95% CI 0.40 to 0.98, *p* = 0.043, for each) (Table [4](#Tab4){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). The carriers of the minor alleles of these SNPs (A and A, respectively) had a decreased risk of developing AKI. This association was in the same direction as in the previous report. The minor allele frequencies of all investigated SNPs in patients with septic shock are presented in Fig. [2](#Fig2){ref-type="fig"}.Table 4Association between acute kidney injury and the polymorphisms studied in 478 patients in septic shock (additive genetic model)Single nucleotide polymorphismUnivariate odds ratio (95% confidence interval)Univariate\
*P* valueMultivariate odds ratio (95% confidence interval)^a^Multivariate\
*P* valuers6251450.81 (0.59--1.11)0.190.80 (0.56--1.13)0.20rs19556560.71 (0.46--1.07)0.100.63 (0.40--0.98)0.043rs20932660.71 (0.46--1.07)0.100.63 (0.40--0.98)0.043rs80943151.19 (0.88--1.62)0.271.13 (0.81--1.58)0.48rs124578931.24 (0.94--1.62)0.131.22 (0.91--1.64)0.19^a^Adjusted for body mass index, use of non-steroidal anti-inflammatory drugs as daily medication, arteriosclerosis, chronic obstructive pulmonary disease, administration of contrast medium prior to ICU admission, administration of colloids prior to ICU admission, simplified acute physiology score II without age or renal components, operative admission, and source of infection Fig. 2Minor allele frequencies of all polymorphisms studied in patients with septic shock (n = 478). Patients (*red*) had severe acute kidney injury (AKI) (Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 or 3 AKI, n = 252) and controls (*blue*) were ICU patients without AKI. The *p* values shown above the *bars* are for the multivariate tests of association between the polymorphisms and AKI. \*Significant *p* values

When the same analyses were performed in the entire genetic cohort, there was no evidence of association between any of the SNPs and AKI in univariate or multivariate models when adjusting for clinical and demographic variables that remained significant in logistic regression (Additional files [7](#MOESM7){ref-type="media"} and [8](#MOESM8){ref-type="media"}).

Using recessive and dominant genetic models did not change the results: SNPs rs8094315, rs12457893 and rs625145 were not associated with AKI in any of the subgroups studied. The protective association with SNPs rs2093266 and rs1955656 prevailed in patients in septic shock in the dominant adjusted model (OR 0.59, *p* = 0.034, for each) (Additional file [9](#MOESM9){ref-type="media"}). The self-assessed quality score of the study was 9/10 \[[@CR18]\] (Additional file [10](#MOESM10){ref-type="media"}).

Discussion {#Sec13}
==========

In this study we confirmed the previously reported association between AKI and two polymorphisms, rs2093266 and rs1955656 in apoptosis-related genes *SERPINA* 4 and *SERPINA5* in patients with septic shock. Both in our study and in the original study the minor alleles of these SNPs provided protection from AKI. The association signal was seen in both additive and dominant genetic models but not in the recessive model, suggesting that merely one protective allele is sufficient.

Our study was based on a previous report suggesting that polymorphisms within apoptosis-related genes may be associated with the development of AKI. In this study comprising 887 patients with septic shock, AKI was associated with five SNPs \[[@CR11]\]. To our knowledge this is the first successful replication of two of these SNPs. There was no evidence in our cohort of significant association between AKI and the other three polymorphisms tested, rs8094315, rs12457893, and rs625145.

The SNP rs2093266 is located in an intronic region of *SERPINA4* gene encoding kallistatin, a serine proteinase inhibitor that has multiple regulatory roles in biological processes \[[@CR19], [@CR20]\]. In kallistatin there are two functional domains, an active site and a heparin-binding site, through which it regulates several signaling and biological pathways. Along with its functions in relation to apoptosis, it has anti-inflammatory, antioxidant, vasodilator and angiogenesis inhibiting functions \[[@CR21]\]. All these mechanisms are relevant in septic AKI and could thus explain the better outcome.

In recent mouse model studies, Kallistatin has been associated with attenuated inflammation and organ injury and decreased mortality in established sepsis \[[@CR22]\], and with improved survival in sepsis-related acute lung injury \[[@CR23]\]. Of note, it may also have a renoprotective role against diabetic nephropathy \[[@CR24]\]. rs1955656 in *SERPINA5* is strongly correlated with rs2093266 and as suspected before, this association with AKI could be driven by rs2093266. Notably, the product of *SERPINA5* is known to inhibit activated protein C. This protein C inhibitor (PCI) plays a role in tumor growth and metastasis through its effect on blood coagulation, but it has also been suggested to inhibit the anti-inflammatory activity of activated protein C \[[@CR25], [@CR26]\]. This inflammatory function could possibly explain the protection against septic AKI.

Of the other three SNPs studied, two (rs8094315 and rs12457893) are located in the introns of the apoptosis-related gene *BCL2* encoding an integral outer mitochondrial membrane protein BCL2 that blocks the apoptotic death of certain cells \[[@CR27]\]. The SNP rs625145 is in *SIK3*, coding for a member of the AMP-activated protein kinase family that affects the regulation of several genes. This protein is found to suppress inflammatory molecule gene expression in macrophages stimulated with lipopolysaccharides (LPS) \[[@CR28]\].

There is no definite consensus on the pathophysiology of AKI, and until recently the most common approach has been to test for association with known genetic variants. These variants have often come up in another phenotype, commonly chronic kidney disease, and, thus, may serve as poor markers of AKI \[[@CR29], [@CR30]\]. So far, the most studied polymorphisms are within inflammatory mediator genes \[[@CR10]\].

Apoptosis-related genes are good candidates for AKI because there is some evidence that apoptosis is an important mechanism in septic AKI. In a murine model of septic AKI the pathophysiology appears to differ from that of ischemia-reperfusion insult, lacking signs of tubular cell injury by necrosis but showing a substantial number of tubular cells undergoing apoptosis \[[@CR31]\]. Lerolle et al*.* found that in post-mortem kidney biopsies of patients who died of septic shock (n = 19) there was a marked increase in apoptosis and capillary leukocytic infiltration in comparison with patients with trauma and ICU controls \[[@CR32]\]. However, there were contradicting results in a separate sample of post-mortem kidney biopsies in patients who died of sepsis \[[@CR33]\]. The nature of septic AKI alone appears to be diverse, with temporal and individual variation, and the role of apoptosis is inconclusive \[[@CR34]\].

We also tested the association between the five SNPs and development of AKI in all patients with sepsis, but the results were negative. The phenotype of septic shock differs from that of sepsis without shock, reflecting a more severe form of illness and a greater risk of death. Thus, we can speculate that the associations between SNPs and AKI detected in these patients, although not generalizable to the septic cohort, can predict better survival for the carriers of the protective allele in terms of AKI.

The strength of our study is that it was a prospective, relatively large, multicenter study comprising consecutive patients. In addition we used the KDIGO criteria to provide a robust phenotype of AKI and critically ill patients without AKI as controls to increase the power of our study.

There are some important limitations in our study. First, 171 genetic samples (5.8%) could not be analyzed due to failure in the DNA isolation phase or to rejection of samples because of a low genotyping success rate. Second, we did not collect data ont ethnicity. However, 99.9% of Finnish-speaking inhabitants are Caucasian. Third, individual genetic susceptibility factors can be expected to increase the AKI risk with values just exceeding an OR of 1 \[[@CR35]\]. In our power calculations we used the ORs reported in the original study, and, thus, our study might have been underpowered to replicate the results for *BCL2* and *SIK3*. Fourth, we did not adjust the *p* values for multiple testing, in this replication of positive findings.

Finally, in contrast to the previous study \[[@CR11]\] we excluded patients with chronic kidney disease. Furthermore, we aimed to strengthen the phenotype by comparing patients without AKI to patients with more severe AKI (KDIGO stage 2--3), thus excluding those with KDIGO stage 1. We reasoned that this group would include patients with only KDIGO stage-1 urine output (not included in \[[@CR11]\]) criteria, whose phenotype clearly differs from that of more severe acute kidney.

These findings provide some interesting questions for future research. The functions of the SNPs rs2093266 in the *SERPINA4* and rs1955656 in the *SERPINA5* for the protein products are yet to be determined. If further studies can provide independent evidence supporting the role of these SNPs in AKI susceptibility, information about the genotype of either of these SNPs may add to the battery of risk-predicting tools. However, the effect size of the SNPs is too small for the genotype information to work as an independent biomarker in a clinical setting.

Conclusions {#Sec14}
===========

In this study we aimed to replicate the previous findings associating polymorphisms within apoptosis-related genes to AKI. We found that SNPs rs2093266 in the *SERPINA4* and rs1955656 in the *SERPINA5* were associated with KDIGO stage 2--3 AKI in critically ill patients in septic shock.
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ARB

:   Angiotensin receptor blocker
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:   Deoxyribonucleic acid

FIMM
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:   Odds ratio
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SIK3

:   Salt-inducible kinase family 3
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